Myriad Genetics: Sum‑of‑the‑Parts Re‑Rate Could Double the Stock If MRD Commercialization Gains Traction

Hook & thesis

Myriad Genetics (MYGN) is priced like a legacy diagnostics company with little growth optionality: market cap ~$421M and P/S ~0.49. That price implicitly discounts the company's near-term commercial product Precise MRD and continued rollouts in carrier/reproductive testing. If the market assigns even a modest premium for successful MRD commercialization and steady growth in multi-gene panels, the stock is significantly undervalued.

This is a long idea built around a sum-of-the-parts re-rate. Buy at the market here to capture optionality from MRD commercialization and product expansion, but size the position for execution risk: Myriad is unprofitable, FCF negative, and has elevated short interest. The trade has a clear stop and a multi-month time horizon designed to let commercialization and data catalysts play out.

What the company does and why it matters

Myriad Genetics develops and markets molecular diagnostic tests across oncology, hereditary cancer, carrier screening and reproductive genetics. The business combines recurring, reimbursed hereditary and reproductive testing with higher-growth esoteric diagnostics and, now, circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing under the Precise MRD brand. Investors should care because MRD is a high-value, high-margin clinical application: if adopted, MRD can change treatment sequencing and generate recurring revenue streams tied to cancer surveillance.

The broader markets that intersect with Myriad are growing: SNP genotyping, pan-genomic and multi-gene panels, and esoteric testing are all expected to expand meaningfully over the coming years. Those secular tailwinds mean Myriad is selling into growing end markets even as it navigates reimbursement and competitive pressures.

Hard numbers that frame the opportunity

Put simply: the market is valuing the entire company at less than 0.5x trailing sales, or an enterprise value roughly in the high $300M range. Converted to revenue terms, that implies trailing revenue in the neighborhood of $820M–$860M (EV/Sales 0.46 and P/S 0.49 suggest the same order of magnitude). For a company with an emerging MRD franchise and steady hereditary/reproductive testing revenue, that multiple feels conservative.

SOTP framing without headline-making assumptions

Instead of building a detailed segment forecast from limited public disclosures, treat the current multiple as a starting point. If Myriad's business mix and growth prospects earned the market a modest re-rating to a 1.0x P/S multiple, the market cap would roughly double. A re-rate to 1.5x would imply even larger upside. The path to a re-rate is straightforward: visible MRD revenue, early reimbursement wins, and consistent organic growth in existing testing lines.

Catalysts (what can re-rate the stock)

• Commercial launch and early adoption of Precise MRD - the company announced advancement toward a March 2026 launch and published supportive clinical data (Precise MRD data highlighted in an announcement on 02/16/2026).
• Published clinical validation and peer-reviewed outcomes - Myriad already had MRD data published in The Lancet Oncology (09/04/2025), which helps build physician acceptance.
• Reimbursement clarity - CMS/LGG or private payer coverage decisions materially increase addressable market and shorten time to revenue.
• Product expansion & cross-sell - additions to carrier panels (e.g., Foresight updates) increase per-patient revenue and stickiness.
• Quarterly results and guidance - predictable revenue beats and improved free cash flow will drive multiple expansion.

Trade plan (actionable)

Entry: Buy at $4.50. This is the current last price and offers a clean round price to execute from.

Stop: $3.60. This level sits below recent support and the 52-week low of $3.76, giving the commercialization story room to develop while protecting from structural downside if adoption stalls or near-term results disappoint.

Target: $8.00. This target assumes a conservative partial re-rate toward ~1.0x P/S with some MRD upside priced in over the next several quarters. Exiting at $8.00 captures meaningful upside while leaving room to extend if MRD adoption accelerates.

Time horizon: long term (180 trading days). I expect commercialization, reimbursement progress, and early traction metrics to unfold over multiple quarters. This is not a short-term quick flip; give the company time to show repeatable revenue from MRD and improved operating leverage.

Operationally, consider scaling in: initial position at entry with a plan to add on clear evidence of commercial MRD billing or a material payer coverage win. Trim to half of the position at $6.00 as a near-term profit-taking and risk management point.

Why this trade has asymmetric upside

Myriad trades with an enterprise value under $380M while owning an established hereditary testing franchise and an MRD product that, if adopted, plays into a higher-value, recurring surveillance revenue stream. Small moves in assigned multiples (from 0.5x P/S to 1.0x P/S) translate into large percentage upside because the company is already modestly sized. The combination of stable base revenue and disproportionate upside from a successful MRD takeoff creates an asymmetric risk/reward profile.

Risks and counterarguments

• Execution & commercialization risk: New diagnostic launches frequently take longer than expected to reach scale. MRD adoption requires clinician education, integration into care pathways, and payer reimbursement.
• Reimbursement pressure: Diagnostic reimbursement is volatile. Slow or unfavorable coverage decisions would limit revenue and keep the valuation compressed.
• Financial losses and cash flow: Trailing EPS is negative (-$3.91) and free cash flow is negative (~-$13.8M). Continued losses could pressure the stock if growth does not materialize.
• Competition and technical risk: MRD and NGS-based diagnostics are crowded fields. Competitors with superior data or broader payer relationships could capture share.
• Market & sentiment risk: Technical indicators are not bullish (RSI ~43, MACD shows bearish momentum) and short interest is elevated (short interest ~11.7M as of 03/13/2026), which can amplify downside on negative news.

Counterargument: the market is correct to apply a low multiple because Myriad is still unprofitable with negative free cash flow and declining margins in some legacy test lines. If MRD growth disappoints, the re-rate will not happen and the current valuation could prove fair or rich relative to fundamentals.

What would change my mind

I would downgrade this idea if Myriad reports material MRD commercialization setbacks (poor reimbursement outcomes, weak early uptake), or if free cash flow materially worsens such that balance sheet stress forces dilutive financing. Conversely, repeated quarter-over-quarter MRD billing growth, payer coverage decisions, and improving free cash flow would strengthen the bullish case and justify a higher target.

Bottom line

Myriad is a classic optionality trade: a profitable-ish hereditary/reproductive testing franchise combined with an MRD product that could re-rate the business if reimbursed and adopted. The company is small enough that even limited MRD success could meaningfully re-value shares. Buy at $4.50 with a $3.60 stop and an $8.00 target over a 180 trading day horizon, size conservatively, and treat early MRD commercialization metrics as the primary evidence that the thesis is playing out.

Key catalysts and timeline

• Early MRD commercial traction and billing data (next several quarters).
• Payer coverage or reimbursement clarifications (ongoing).
• Quarterly results showing revenue growth and improving cash flow (each quarterly report).
• Peer-reviewed outcomes and broader clinical adoption signals (ongoing).

Trade plan recap: Buy $4.50, Stop $3.60, Target $8.00. Time horizon: long term (180 trading days).